Both cyclic GMP-dependent protein kinase (cGK) and cyclic AMP-dependent protein kinase (cAK) contain two distinct cyclic nucleotide-binding sites referred to as fast and slow sites based on cyclic nucleotide dissociation behavior. In cAK, the fast site lies amino-terminal to the slow site, and sequence homologies between cAK and cGK have suggested similar positioning for the sites in cGK. Recombinant human type I cGK (wild type (WT) cGK) was overexpressed, and the properties of purified WT cGK and native type I cGK were similar. cGK was mutated singly at Thr-193 (T193A, T193V, and T193S) and Thr-317 (T317A, T317V, and T317S), which have been predicted to provide cGMP specificity in the cGMP-binding sites of cGK; a double mutant (T193A/ T317A) was produced also. Compared with WT cGK, half-maximal activation (K a ) of mutant cGKs by cGMP was increased 2-(T317A), 27-(T193A), or 63-fold (T193A/ T317A), but the K a for cAMP of these mutants was essentially unchanged. The T193A and T193V mutants had a large increase in the rate of the slow component of The cGMP-dependent protein kinase (cGK) 1 and cAMP-dependent protein kinase (cAK) are homologous enzymes that are preferentially activated by cGMP and cAMP (1), respectively, although cross-activation of either cGK by cAMP (2) or cAK by cGMP (3) has been demonstrated under physiological and pathological conditions. The two cyclic nucleotide-binding sites in cAK preferentially bind cAMP over cGMP with a Ͼ50-fold selectivity, have different cAMP analog specificities, and have different dissociation rates for cAMP (4 -7). Because of the latter feature, these cAMP-binding sites generally have been referred to as the fast and slow cAMP-dissociation sites (see Footnote 2 of Ref. 8). Biochemical studies of type II cAK first suggested that the more amino-terminal cyclic nucleotide-binding site is the fast site whereas the adjacent site is the slow site (9), and similar approaches were used to demonstrate the same structural order for the binding sites of type I cAK (10). Molecular modeling (11) and results of site-directed mutagenesis of the binding sites (12, 13) supported these findings.Like cAK, each subunit of cGK (Fig. 1, top) contains two cyclic nucleotide-binding sites that are homologous in sequence but have distinct kinetic characteristics. The cyclic nucleotidebinding sites of cGK preferentially bind cGMP over cAMP with a Ͼ100-fold selectivity, have different cGMP analog specificities, and have extremely different dissociation rates for cGMP (14). Additionally, these sites show significant amino acid sequence homology to the two kinetically distinct cAMP-binding sites of cAK. The more amino-terminal site of cGK shows higher homology to the more amino-terminal site of cAK, and conversely, the more carboxyl-terminal site of cGK shows higher homology to the more carboxyl-terminal site of cAK (15). Based solely on the sequence homology between the cyclic nucleotide-binding sites in cAK and cGK, it has been thought that the more amino-terminal cGMP-binding site of cGK is...